Pharma Minds

Nathalie Lahitte
  • 0.0 (0)
  • Careers
  • Updated Weekly

Bienvenue dans Pharma minds, le podcast qui vous emmène dans une aventure captivante à travers la Pharma et la Santé d'aujourd'hui ! Je suis votre hôte, Nathalie Lahitte. Mon objectif ? Découvrir comment des personnalités influentes ont contribué à façonner ce secteur. À chaque épisode, nous plongeons dans leurs caractéristiques uniques, dévoilant les secrets de leurs parcours exceptionnels et leur rôle dans les grandes transformations de cet écosystème. Explorez les coulisses de l'évolution de la Pharma et de la Santé à travers des discussions authentiques et percutantes. Ensemble, nous construisons l'avenir de ce secteur fascinant en le rendant plus innovant et inclusif. Rejoignez-nous pour des épisodes inspirants et motivants, et soyez aux premières loges de la Santé de demain. 🎧 Vous êtes nouveau par ici ? Pour comprendre en un clin d'œil le panorama des épisodes, téléchargez « 25 conseils pour un leadership engagé (https://pharma-minds.kit.com/ebookleadership) », un guide inspiré des meilleurs conseils de mes invités. 🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn (https://www.linkedin.com/in/nathalielahitte/). 📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds (https://nathalielahitte.substack.com/). Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

  1. 2d ago

    #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur

    Et si standardiser les flux de patients permettait de mieux les soigner ? Dans cet épisode de Pharma minds, je reçois Loïc Lagarde, directeur général de la Clinique Pasteur à Toulouse. Ingénieur de formation, passé par Google, YouTube et l’entrepreneuriat avec Santé Discount, il apporte un regard différent sur l’organisation des établissements de santé. À la Clinique Pasteur, ce regard se traduit par une conviction forte : pour mieux personnaliser les soins, il faut d’abord savoir standardiser ce qui peut l’être. Au programme de cet épisode : ◾️ Un modèle économique atypique : pourquoi la Clinique Pasteur réinvestit ses résultats depuis 70 ans et comment cette indépendance favorise l’investissement et la prise de risque. ◾️ Le patient comme un flux : comment organiser les parcours selon leur vitesse et leurs besoins, plutôt que de faire passer tout le monde par les mêmes circuits. ◾️ La standardisation au service de l’humain : pourquoi regrouper les prises en charge qui se ressemblent permet de libérer du temps soignant et de mieux personnaliser les autres. ◾️ L’innovation concrète à l’hôpital : robotisation de la pharmacie à usage intérieur, optimisation de la logistique et développement de l’hospitalisation à domicile. ◾️ De nouveaux rôles dans le soin : ce que l’expérimentation autour des maladies chroniques révèle sur l’accompagnement et la motivation des patients. ◾️ Conduite du changement et management : comment faire évoluer les pratiques, dépasser les résistances et pourquoi les ressources humaines sont aussi l’affaire des dirigeants. ◾️ Digitalisation et intelligence artificielle : quelle place donner à la technologie dans un système où le temps humain reste essentiel. Derrière ces projets, un objectif guide, selon Loïc Lagarde, 95 % de ses décisions : libérer du temps soignant. Une conversation sur ce que l’ingénierie et une autre approche du management peuvent apporter à la santé, sans perdre de vue l’essentiel : le patient et la relation de soin. Merci à notre partenaire BD France pour son soutien dans cet épisode, qui nous permet d’ouvrir le dialogue autour de l’innovation et des enjeux de santé. La ligne éditoriale reste entre nos mains. Pour retrouver Loïc Lagarde : LinkedIn : https://www.linkedin.com/in/llagarde/ La Clinique Pasteur : https://www.clinique-pasteur.com/ Ressources mentionnées : 📌 Santé Discount (devenue Atida maintenant) : https://www.atida.fr/ 📌 L'expérimentation Constel'Action : un dispositif autour de l’accompagnement des personnes atteintes de maladies chroniques et de leur parcours de soins. -- 🤝 Retrouvez-moi sur LinkedIn. 📩 Abonnez-vous à la newsletter Pharma Minds. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    #53 - Libérer du temps soignant : le pari d'un ingénieur à la Clinique Pasteur

  2. 3d ago

    [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde

    Comment faire accepter le changement sans que les équipes aient le sentiment que leur travail passé est remis en question ? Pour Loïc Lagarde, dirigeant de la Clinique Pasteur à Toulouse, changer ne signifie pas que ce qu’on faisait avant était mauvais. Cela signifie que nos pratiques doivent évoluer pour s’adapter à la réalité d’aujourd’hui. Mais avant de transformer quoi que ce soit, il faut accepter de regarder les choses telles qu’elles sont. Et c’est aussi le rôle d’un dirigeant : porter un miroir, plutôt que chercher des coupables. Rendez-vous demain pour découvrir l'épisode complet ! Et pour les plus curieux, voici un sneak peek de ce que vous allez découvrir : ◾️ Un modèle économique atypique : pourquoi la Clinique Pasteur réinvestit ses résultats depuis 70 ans et comment cette indépendance favorise l’investissement et la prise de risque. ◾️ Le patient comme un flux : comment organiser les parcours selon leur vitesse et leurs besoins, plutôt que de faire passer tout le monde par les mêmes circuits. ◾️ La standardisation au service de l’humain : pourquoi regrouper les prises en charge qui se ressemblent permet de libérer du temps soignant et de mieux personnaliser les autres. ◾️ L’innovation concrète à l’hôpital : robotisation de la pharmacie à usage intérieur, optimisation de la logistique et développement de l’hospitalisation à domicile. ◾️ De nouveaux rôles dans le soin : ce que l’expérimentation autour des maladies chroniques révèle sur l’accompagnement et la motivation des patients. ◾️ Conduite du changement et management : comment faire évoluer les pratiques, dépasser les résistances et pourquoi les ressources humaines sont aussi l’affaire des dirigeants. ◾️ Digitalisation et intelligence artificielle : quelle place donner à la technologie dans un système où le temps humain reste essentiel. __ 📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds. 🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn. Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    [EXTRAIT] « On a toujours fait comme ça » : comment faire accepter le changement ? avec Loïc Lagarde

  3. Oct 12

    "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

    What if Europe’s “innovation wave” isn’t quite what we think it is? In this bonus episode of Pharma minds’ Europe’s Access Dilemma, I speak with Dr. Sabine Vogler, health economist, Head of the Pharmacoeconomics Department at the Austrian National Public Health Institute (GÖG) and of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies in Vienna. After five episodes looking at Europe’s access dilemma from the perspective of industry, research and consulting, this conversation brings in a very different voice: someone who advises policymakers and public payers. We start with a fundamental question: what does access actually mean? Regulatory approval is only the beginning. A medicine also needs to be available and affordable. From there, Sabine challenges some of the assumptions behind the current debate around pharma innovation, drug pricing and access in Europe: ◾️ Why a new medicine is not necessarily an innovative one ◾️ What evidence should really justify a higher price ◾️ Whether Europe could ever move towards a more coordinated pricing model ◾️ What confidential discounts mean for public payers ◾️ And whether industrial policy and innovation should really be financed through medicine prices She also explains why horizon scanning could help European payers prepare much earlier for the medicines coming through the pipeline. A bonus episode that doesn't necessarily give the same answers as the rest of the series — but asks some uncomfortable questions about what Europe is actually paying for, and how we define innovation in the first place. 👉To find Sabine Vogler: https://www.linkedin.com/in/sabine-vogler-8ba943254/Resources mentioned in the episode: 📌 WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies (GÖG, PPRI): https://ppri.goeg.at/whocc📌 Study on enhanced cross-country coordination in the area of pharmaceutical product pricing (European Commission, 2016): https://health.ec.europa.eu/latest-updates/study-enhanced-cross-country-coordination-area-pharmaceutical-product-pricing-2016-02-24_en📌 Davis et al., BMJ 2017, cancer drugs approved by the EMA without clear evidence of survival or quality-of-life benefit: https://www.bmj.com/lookup/doi/10.1136/bmj.j4530📌 International Horizon Scanning Initiative (IHSI): https://ncpe.ie/international-collaborations/international-horizon-scanning-initiative/📌 Also cited: BeNeLuxA, the Nordic Pharmaceutical Forum, the European HTA regulation and its joint clinical assessments (JCA) ___ 📩 Subscribe to the newsletter: https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (BONUS) - The Innovation Wave? Europe’s Payers Aren’t Convinced

  4. Oct 5

    "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?

    "The worst of all outcomes is the current default: the level of Europe's contribution to the world will be decided by America." – Graham Cookson, Economist Welcome to the 5th episode of Europe's Access Dilemma, the Pharma Minds mini-series on MFN and access to innovation in Europe. Pay more. Wait longer. Or change the model. Europe wants three things at once: medicines people can afford, fast access to new drugs, and a strong pharma industry. Is that still possible? My guest is Graham Cookson, Chief Executive of the Office of Health Economics (OHE) in London. He is an econometrician who works on healthcare efficiency, drug pricing and reimbursement. He starts with Germany, the country at the center of MFN. What you will learn in this episode: Germany's trilemma: a big buyer with a budget hole, a big producer of innovation, and a big exporter to the US. That is why it has "a target on its back".The MFN paradox: why MFN should push US prices down, and why it is really about US revenues.Something has to give: low prices, the latest drugs and more investment are not compatible in the short run.The UK deal: paying more for medicines in exchange for tariff relief and investment.No single European price: what a "NATO-style" agreement could look like instead.The hidden trade-offs: why the worst outcome is letting America decide what Europe pays.Health as an investment: why Europe can act as 27 nations, or as one bloc. Listen to this episode for a European economist's view of pharma's big picture today: which ways out Europe still has, and what each one will cost. Ressources: 📌 "FOIA Documents: Trump-Pharma MFN Drug Pricing Deals": https://www.citizen.org/article/foia-documents-trump-pharma-mfn-drug-pricing-deals/ 📌 Office of Health Economics (OHE): https://www.ohe.org 📖 Read Graham's article: Germany's drug-pricing dilemma: Why Europe's pivotal market holds the key to the MFN debate (OHE, June 2026)https://www.ohe.org/insights/germanys-drug-pricing-dilemma-why-europes-pivotal-market-holds-the-key-to-the-mfn-debate/ ___ 📩 Subscribe to the newsletter: https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (5/5) - "Germany has a target on its back" What will Europe give up?

  5. Sep 28

    "Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3

    What happens to pharmaceutical innovation when your competitive window shrinks from eight years to just three? In this episode of Pharma minds, I speak with Marine Baxendell, CFO and co-fonder at xcube.bio, about a fundamental shift in the economics of pharma innovation. Science is moving faster. Competition is accelerating. And at the same time, MFN pricing, healthcare budget pressures and increasingly complex market access are challenging the traditional model on both sides of the Atlantic. An innovative treatment could once expect five to eight years before serious competition entered the same space. Today, Marine argues, that window can be closer to two or three years, even while the original molecule remains protected.  So what happens when the time available to capture the value of innovation gets shorter? We explore: ◾️ Why the next wave of pharma innovation is structurally different ◾️ What MFN reveals about the limits of today’s pricing model ◾️ Why demonstrating patient value earlier is becoming critical ◾️ What is really slowing market access in Europe ◾️ Why being first to market may no longer be enough ◾️ And what a more sustainable model for pharma, payers and patients could look like Marine’s perspective reframes MFN not simply as a threat, but as a signal that the rules of pharmaceutical innovation are changing. This is episode #4 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. To find Marine Baxendell:  LinkedIn: https://www.linkedin.com/in/marine-baxendell/ Resources mentioned in the episode: 📌 xcube.bio : https://xcube.bio/ ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (4/5) - Pharma Innovation: Your 8-Year Competitive Window Is Now Just 3

  6. Sep 21

    "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

    MFN isn't just a pricing debate. It is already changing how pharma companies think about where, when and how they launch new medicines. In this episode of Pharma minds, I speak with Laure Nas de Tourris, Partner at Clarivate, about what she is seeing on the ground as pharma and biotech leaders start adapting their commercial strategies to the new Most Favored Nation (MFN) environment. And one thing is clear:uncertainty is here to stay. From early-stage assets to upcoming launches and portfolio decisions, MFN is forcing companies to rethink the traditional launch playbook. US and European pricing have always been interconnected, but those links now need to be considered much more intentionally, and much earlier, from Phase I or II of development. Launch sequencing is becoming more complex, requiring teams to anticipate the impact across markets from the very beginning. We explore: ◾️ Why MFN has become a top-of-mind issue for pharma leaders ◾️ How MFN is already changing global launch sequencing ◾️ Why even rare disease and early-stage assets may need to prepare ◾️ How scenario planning can help teams navigate regulatory and pricing uncertainty ◾️ Why commercial, market access, medical and other functions need to work together much earlier ◾️ How pharma companies can build more flexible go-to-market models ◾️ When it may make sense to deprioritize an indication, market or investment ◾️ What delayed launches could ultimately mean for patient access to innovation ◾️ And why “wait and see” may be one of the riskiest strategies of all The companies best prepared for what comes next will not necessarily be those that correctly predict exactly how MFN will unfold. They will be those that build different scenarios, preserve optionality, connect decisions across their portfolio and prepare their teams early. Because under MFN, the old launch playbook may not be enough. This is episode #3 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. To find Laure Nas de Tourris: LinkedIn: https://www.linkedin.com/in/laurenasdetourris/ MFN as a Catalyst for Strategic Reinvention https://clarivate.com/life-sciences-healthcare/wp-content/uploads/sites/4/dlm_uploads/2026/09/MFN-as-Catalyst-for-Reinvention-Clarivate.pdf___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (3/5) - MFN Is Already Changing Pharma Launch Strategy. Here’s How to Prepare.

  7. Sep 14

    "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia

    What if Europe’s answer to the rising cost of pharmaceutical innovation wasn’t simply to pay more, but to develop differently? In this episode of Pharma minds, I speak with Franck Le Deu, one of the few European voices with decades of first-hand experience inside Asia’s rapidly evolving biopharma ecosystem. Franck spent 20 years in China as a Senior Partner at McKinsey, advising some of the world’s largest pharmaceutical companies as China transformed from a market for Western medicines into a global source of biopharma innovation. Today, he is working on building bridges between Western innovation and Asian capabilities. That transformation is at the heart of our conversation.  Because Europe faces an uncomfortable equation. The pharmaceutical industry has become increasingly US-centric. The majority of its profits are generated in the US, investment has followed, and Europe has progressively lost influence. At the same time, European governments face growing fiscal constraints, making simply spending more on innovative medicines increasingly difficult.  Franck makes the case for another path: co-development with Asia. We explore: ◾️ How China became one of the world’s leading biopharma innovation ecosystems ◾️ Why US pharma is moving faster than Europe to tap into Chinese biotech innovation ◾️ How Asia could help reduce the cost and accelerate the execution of clinical trials and drug development ◾️ Why Europe can no longer afford to look at China only as a competitive threat ◾️ What Europe–Asia co-development could look like in practice ◾️ How Europe could combine Asian capabilities with its own strengths in research, development and manufacturing ◾️ And whether this model could help Europe regain pharmaceutical competitiveness while protecting its sovereignty Franck’s argument is not that Europe should replace its relationship with the US with China. It is that Europe needs to engage with Asia strategically, learn from ecosystems that move faster, and build new forms of collaboration that preserve European strengths and sovereignty. Ultimately, making pharmaceutical innovation accessible to more patients will require more than higher budgets. It means bringing R&D and manufacturing costs down, rethinking pricing, and creating ecosystems that know how to collaborate and compete. This is episode #2 of Europe’s Access Dilemma: five perspectives on how Europe can make innovation affordable. Franck Le Deu: https://www.linkedin.com/in/franck-le-deu/ Resources mentioned in the episode: 📌 PhRMA Forum 2026 - “China’s Leading Edge: What’s at Risk” : https://www.innovation.org/phrma-forum/ 📌 “Europe’s narrow path between the U.S. and China in biotech”, an article from Franck Le Deu, BioCentury : https://www.biocentury.com/article/659819/ Further reading from Franck Le Deu: 📌 “In support of a multipolar biopharma world: Guest Commentary", BioCentury : https://www.biocentury.com/article/658573 ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (2/5) - Europe Can't Pay More For Innovation: The Case For Co-developing With Asia

  8. Sep 7

    "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.

    What happens when making medicines cheaper in the US makes Europe less attractive for pharmaceutical innovation? In this episode of Pharma minds, I speak with Christoffer Frendesen, a Brussels-based pharmaceutical journalist specializing in pricing and market access, about one of the most consequential questions facing Europe’s pharmaceutical market: what happens when the rules of global drug pricing change? Trump’s Most Favored Nation (MFN) policy is putting pressure on pharmaceutical prices in the US. But the consequences may extend far beyond American patients, and Europe may end up paying part of the price. Christoffer explains what he is hearing from industry and policy experts, and why delayed launches and higher prices in Europe may not be temporary effects. In some European countries, fewer new medicines are already being launched, raising a fundamental question about access to innovation. We also explore: ◾️ Why Europe is struggling to speak with one voice on pharmaceutical pricing and market access ◾️ Whether national pricing and reimbursement systems are still sustainable ◾️ Whether a more coordinated European pricing and reimbursement system could improve access ◾️ Why the EU’s Biotech Act may not be enough to make Europe attractive for pharmaceutical R&D and manufacturing ◾️ And why the consequences of MFN could be much more permanent than a Trump presidency.  This is not simply a story about Trump or pricing. It is a conversation about Europe’s pharmaceutical competitiveness, access to innovation, and the choices Europe will have to make if it wants to remain an attractive market for the medicines of tomorrow. To find Christoffer Frendesen: LinkedIn Resources mentioned in the episode: 📌 Trump’s Most Favored Nation (MFN) policy: https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-with-nine-additional-pharmaceutical-manufacturers-to-lower-drug-prices-for-americans/ 📌 The EU Critical Medicines Act: https://health.ec.europa.eu/medicinal-products/critical-medicines-act_en 📌 The EU Biotech Act: https://health.ec.europa.eu/biotechnology/european-biotech-act_en 📌 GlobalData - March 2026https://www.pharmaceutical-technology.com/analyst-comment/most-favored-nation-policy-early-insights-into-europe-response/📌 IQVIA - July 2026https://www.iqvia.com/locations/emea/blogs/2026/07/tracking-mfns-impact-on-innovative-medicine-launches ___ 📩 Subscribe to the newsletter : https://nathalielahitte.substack.com/ Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

    "Europe's Access Dilemma" (1/5) - Europe Is Losing Access to New Medicines. Here’s Why.
See All (145)

Trailers

About

Bienvenue dans Pharma minds, le podcast qui vous emmène dans une aventure captivante à travers la Pharma et la Santé d'aujourd'hui ! Je suis votre hôte, Nathalie Lahitte. Mon objectif ? Découvrir comment des personnalités influentes ont contribué à façonner ce secteur. À chaque épisode, nous plongeons dans leurs caractéristiques uniques, dévoilant les secrets de leurs parcours exceptionnels et leur rôle dans les grandes transformations de cet écosystème. Explorez les coulisses de l'évolution de la Pharma et de la Santé à travers des discussions authentiques et percutantes. Ensemble, nous construisons l'avenir de ce secteur fascinant en le rendant plus innovant et inclusif. Rejoignez-nous pour des épisodes inspirants et motivants, et soyez aux premières loges de la Santé de demain. 🎧 Vous êtes nouveau par ici ? Pour comprendre en un clin d'œil le panorama des épisodes, téléchargez « 25 conseils pour un leadership engagé (https://pharma-minds.kit.com/ebookleadership) », un guide inspiré des meilleurs conseils de mes invités. 🤝 Vous voulez me parler ou échanger sur vos enjeux ? Connectons-nous sur LinkedIn (https://www.linkedin.com/in/nathalielahitte/). 📩 Et si vous voulez aller plus loin dans la compréhension des grandes transformations de l’écosystème pharma et santé, abonnez-vous à la newsletter Pharma Minds (https://nathalielahitte.substack.com/). Hébergé par Ausha. Visitez ausha.co/fr/politique-de-confidentialite pour plus d'informations.

Information

  • Creator
    Nathalie Lahitte
  • Years Active
    2023 - 2026
  • Episodes
    145
  • Rating
    Clean
  • Copyright
    © Nathalie LAHITTE
  • Show Website
    Pharma Minds

You Might Also Like